{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:31:20Z","timestamp":1792071080798,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The differentiation between Alzheimer\u2019s disease (AD) and behavioral-variant frontotemporal dementia (bvFTD) can be complicated in the initial phase by shared symptoms and pathophysiological traits. Nevertheless, advancements in understanding AD\u2019s diverse pathobiology suggest the potential for establishing blood-based methods for differential diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We devised a novel assay combining immunoprecipitation and mass spectrometry (IP-MS) to quantify Amyloid-beta (A\u03b2) peptides in plasma. We then assessed its performance against existing assays (Shimadzu and Simoa) and evaluated a range of other blood-based biomarkers, including GFAP, NfL, and pTau-181, for differentiating between AD and bvFTD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The novel IP-MS assay measuring the A\u03b242\/40 ratio demonstrated an AUC of 0.82 for differentiating AD from control subjects. While it did not significantly outperform the composite biomarker score from the Shimadzu assay (AUC\u2009=\u20090.79, <jats:italic>P<\/jats:italic>\u2009=\u20090.67), it significantly outperformed the Shimadzu A\u03b242\/40 ratio (AUC\u2009=\u20090.65, <jats:italic>P<\/jats:italic>\u2009=\u20090.037) and the Simoa A\u03b242\/40 assay (AUC\u2009=\u20090.57, <jats:italic>P<\/jats:italic>\u2009=\u20090.023). A\u03b2 biomarkers provided limited utility in distinguishing AD from bvFTD. In contrast, pTau181 and GFAP exhibited strong discriminatory power for differentiating AD from bvFTD, with AUCs of 0.90 and 0.87, respectively. Combining pTau181 and GFAP enhanced diagnostic accuracy, achieving an AUC of 0.94.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We introduced a novel IP-MS assay that demonstrated comparable precision to the Shimadzu composite score in differentiating AD from non-neurodegenerative control groups. However, A\u03b2 levels did not enhance the discrimination between AD and bvFTD. Furthermore, our findings support the utility of combining pTau181 and GFAP as a robust strategy for the blood-based differentiation of AD and bvFTD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01647-w","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T22:10:54Z","timestamp":1735596654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Blood-based biomarkers and plasma A\u03b2 assays in the differential diagnosis of Alzheimer\u2019s disease and behavioral-variant frontotemporal dementia"],"prefix":"10.1186","volume":"16","author":[{"given":"Pablo","family":"Mohaupt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kindermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Vialaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anderl-Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"1647_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science"},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377.","journal-title":"Lancet Neurol"},{"key":"1647_CR4","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology. 2024 [cited 2024 Feb 2]; https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"1647_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12:26.","journal-title":"Alzheimers Res Ther"},{"key":"1647_CR6","doi-asserted-by":"publisher","unstructured":"Lehmann S, Schraen-Maschke S, Vidal J-S, Delaby C, Bu\u00e9e L, Blanc F et al. Clinical value of plasma ALZpath pTau217 immunoassay in the assessment of mild cognitive impairment. medRxiv; 2024 [cited 2024 Feb 2]:2024.01.21.24301570. https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2024.01.21.24301570v1","DOI":"10.1101\/2024.01.21.24301570v1"},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P\u2010tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13:e14022.","journal-title":"EMBO Mol Med"},{"key":"1647_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography. JAMA Neurol. 2023;80:188\u201399.","journal-title":"JAMA Neurol"},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging. 2023;3:391\u2013401.","journal-title":"Nat Aging"},{"key":"1647_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E, et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2024;147:12.","journal-title":"Acta Neuropathol"},{"key":"1647_CR11","doi-asserted-by":"publisher","unstructured":"Bellomo G, Bayoumy S, Megaro A, Toja A, Nardi G, Gaetani L et al. Fully automated measurement of plasma A\u03b242\/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer\u2019s disease continuum in two independent cohorts. Alzheimer\u2019s & Dementia. [cited 2024 Feb 13];n\/a. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/alz.13687","DOI":"10.1002\/alz.13687"},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/alz.12949","volume":"19","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal J-S, Allinquant B, Bombois S, Gabelle A, et al. Plasma A\u03b242\/A\u03b240 ratio is independent of renal function. Alzheimer\u2019s Dement. 2023;19:2737\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"1647_CR14","doi-asserted-by":"crossref","unstructured":"Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022 [cited 2024 Feb 14];14. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9107685\/","DOI":"10.1002\/dad2.12285"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea D, Delaby C, Mu\u00f1oz L, Torres S, Estell\u00e9s T, Zhu N, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92:1206\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1647_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-023-01188-8","volume":"15","author":"C Hirtz","year":"2023","unstructured":"Hirtz C, Busto GU, Bennys K, Kindermans J, Navucet S, Tiers L, et al. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer\u2019s disease diagnosis in a memory clinic cohort. Alzheimer\u2019s Res Therapy. 2023;15:34.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377.","journal-title":"Brain"},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1647_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93:651\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1647_CR21","doi-asserted-by":"crossref","unstructured":"Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA et al. Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement. 2022. 2023;19:956\u201366.","DOI":"10.1002\/alz.12697"},{"key":"1647_CR22","doi-asserted-by":"crossref","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601.","DOI":"10.1093\/brain\/awac333"},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481\u20138.","journal-title":"J Alzheimers Dis"},{"key":"1647_CR24","doi-asserted-by":"crossref","unstructured":"Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T et al. Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry. 2022;93:659\u201367.","DOI":"10.1136\/jnnp-2021-328547"},{"key":"1647_CR25","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1212\/WNL.0000000000201597","volume":"100","author":"J Sarto","year":"2023","unstructured":"Sarto J, Ruiz-Garc\u00eda R, Guill\u00e9n N, Ramos-Campoy \u00d3, Falg\u00e0s N, Esteller D, et al. Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort. Neurology. 2023;100:e860\u201373.","journal-title":"Neurology"},{"key":"1647_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L, et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14:153.","journal-title":"Alzheimers Res Ther"},{"key":"1647_CR27","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12790","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimer\u2019s Dement. 2023;19:1358\u201371.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2022","unstructured":"Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain. 2022;146:1152\u201365.","journal-title":"Brain"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","volume":"28","author":"K Horie","year":"2022","unstructured":"Horie K, Barth\u00e9lemy NR, Spina S, VandeVrede L, He Y, Paterson RW, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022;28:2547\u201354.","journal-title":"Nat Med"},{"key":"1647_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1515\/cclm-2023-0659","volume":"62","author":"AL Wojda\u0142a","year":"2024","unstructured":"Wojda\u0142a AL, Bellomo G, Toja A, Gaetani L, Parnetti L, Chiasserini D. CSF and plasma A\u03b242\/40 across Alzheimer\u2019s disease continuum: comparison of two ultrasensitive Simoa\u00ae assays targeting distinct amyloid regions. Clin Chem Lab Med (CCLM). 2024;62:332\u201340.","journal-title":"Clin Chem Lab Med (CCLM)"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01647-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T11:06:42Z","timestamp":1735643202000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01647-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01647-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All individuals or their legal proxies provided written informed consent for inclusion into this study and it was approved by the ethics committee of Ulm University (approval number 39\/11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PO received research support from the Alzheimer Forschung Initiative e.V. (20059CB), ALS Association\/ALS Finding A Cure (24-SGP-691, 23-PPG-674-2)), Charcot Foundation (D.7090), DZNE Innovation-to-Application (I2A_call7_Oeckl, I2A_call9_Oeckl) and consulting fees from LifeArc and Fundamental Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}